Clearmind Medicine

Clearmind Medicine Inc. (NASDAQ:CMND) filed a patent application for its combination therapy involving Ibogaine and N-Acylethanolamines. What Happened: The therapy was developed in collaboration with SciSparc Ltd. (NASDAQ:SPRC). It combines the psychedelic compound Ibogaine with...

Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biotech firm based in Vancouver, has been granted a new patent by the United States Patent and Trademark Office. As the company stated in a press release, this approval marks a significant milestone in Clearmind's efforts to develop...

Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC Pink: CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd. (NASDAQ: SPRC) announced that their collaborative study of cocaine addiction treatment with the non-hallucinogenic psychedelic compound...